⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RCUS News
Arcus Biosciences, Inc.
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
prnewswire.com
RCUS
GILD
AZN
CGEN
CHRS
Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com
RCUS
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
businesswire.com
RCUS
Arcus Biosciences to Participate in the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
RCUS
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
businesswire.com
RCUS
Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com
RCUS
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
businesswire.com
RCUS
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
businesswire.com
RCUS
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
businesswire.com
RCUS